These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 26468380)

  • 1. Comparison of the Effects of Testosterone Gels, Injections, and Pellets on Serum Hormones, Erythrocytosis, Lipids, and Prostate-Specific Antigen.
    Pastuszak AW; Gomez LP; Scovell JM; Khera M; Lamb DJ; Lipshultz LI
    Sex Med; 2015 Sep; 3(3):165-73. PubMed ID: 26468380
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic evaluation and dosing of subcutaneous testosterone pellets.
    Pastuszak AW; Mittakanti H; Liu JS; Gomez L; Lipshultz LI; Khera M
    J Androl; 2012; 33(5):927-37. PubMed ID: 22403285
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men.
    Wang C; Cunningham G; Dobs A; Iranmanesh A; Matsumoto AM; Snyder PJ; Weber T; Berman N; Hull L; Swerdloff RS
    J Clin Endocrinol Metab; 2004 May; 89(5):2085-98. PubMed ID: 15126525
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Testosterone replacement therapy in the setting of prostate cancer treated with radiation.
    Pastuszak AW; Pearlman AM; Godoy G; Miles BJ; Lipshultz LI; Khera M
    Int J Impot Res; 2013 Jan; 25(1):24-8. PubMed ID: 22971614
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The relationship between serum total testosterone and free testosterone levels with serum hemoglobin and hematocrit levels: a study in 1221 men.
    Shin YS; You JH; Cha JS; Park JK
    Aging Male; 2016 Dec; 19(4):209-214. PubMed ID: 27750487
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men.
    Wang C; Swerdloff RS; Iranmanesh A; Dobs A; Snyder PJ; Cunningham G; Matsumoto AM; Weber T; Berman N;
    J Clin Endocrinol Metab; 2000 Aug; 85(8):2839-53. PubMed ID: 10946892
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elevated Dihydrotestosterone is Associated with Testosterone Induced Erythrocytosis.
    Aghazadeh M; Pastuszak AW; Johnson WG; McIntyre MG; Hsieh TM; Lipshultz LI
    J Urol; 2015 Jul; 194(1):160-5. PubMed ID: 25596360
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term pharmacokinetics of transdermal testosterone gel in hypogonadal men.
    Swerdloff RS; Wang C; Cunningham G; Dobs A; Iranmanesh A; Matsumoto AM; Snyder PJ; Weber T; Longstreth J; Berman N
    J Clin Endocrinol Metab; 2000 Dec; 85(12):4500-10. PubMed ID: 11134099
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of raloxifene on gonadotrophins, sex hormones, bone turnover and lipids in healthy elderly men.
    Duschek EJ; Gooren LJ; Netelenbos C
    Eur J Endocrinol; 2004 Apr; 150(4):539-46. PubMed ID: 15080785
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of various modes of androgen substitution on serum lipids and lipoproteins in hypogonadal men.
    Jockenhövel F; Bullmann C; Schubert M; Vogel E; Reinhardt W; Reinwein D; Müller-Wieland D; Krone W
    Metabolism; 1999 May; 48(5):590-6. PubMed ID: 10337859
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Retrospective investigation of testosterone undecanoate depot for the long-term treatment of male hypogonadism in clinical practice.
    Conaglen HM; Paul RG; Yarndley T; Kamp J; Elston MS; Conaglen JV
    J Sex Med; 2014 Feb; 11(2):574-82. PubMed ID: 24279472
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of testosterone formulations on hematocrit in transgender individuals: A systematic review.
    Okano SHP; Braga GC; Cantelli DAL; Filho LASP; Brito LGO; Lara LADS
    Andrology; 2024 Jul; ():. PubMed ID: 39011565
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factors influencing prostate-specific antigen response among men treated with testosterone therapy for 6 months.
    Morgentaler A; Benesh JA; Denes BS; Kan-Dobrosky N; Harb D; Miller MG
    J Sex Med; 2014 Nov; 11(11):2818-25. PubMed ID: 25131184
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of testosterone enanthate on serum lipoproteins in man.
    Anderson RA; Wallace EM; Wu FC
    Contraception; 1995 Aug; 52(2):115-9. PubMed ID: 8536448
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence of secondary erythrocytosis in men receiving testosterone therapy A matched-cohort analysis of intranasal gel, injections, and pellets.
    Reddy R; Diaz P; Blachman-Braun R; Loloi J; Rahman F; Ory J; Dullea A; Zucker I; Gonzalez DC; Kresch E; Ramasamy R
    Can Urol Assoc J; 2023 Jul; 17(7):E202-E207. PubMed ID: 37068153
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Coadministration of anastrozole sustains therapeutic testosterone levels in hypogonadal men undergoing testosterone pellet insertion.
    Mechlin CW; Frankel J; McCullough A
    J Sex Med; 2014 Jan; 11(1):254-61. PubMed ID: 24119010
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Three-year follow-up of androgen treatment in hypogonadal men: preliminary report with testosterone gel.
    Swerdloff RS; Wang C
    Aging Male; 2003 Sep; 6(3):207-11. PubMed ID: 14628501
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral contraceptive tablets containing 20 and 30 micrograms of ethinyl estradiol with 150 micrograms desogestrel. Their influence on lipids, lipoproteins, sex hormone binding globulin and testosterone.
    Akerlund M; Almström E; Högstedt S; Nabrink M
    Acta Obstet Gynecol Scand; 1994 Feb; 73(2):136-43. PubMed ID: 8116352
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Absorption of testosterone gel 1% (Testim) from three different application sites.
    Guay AT; Smith TM; Offutt LA
    J Sex Med; 2009 Sep; 6(9):2601-10. PubMed ID: 19549089
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of demographic factors and biochemical characteristics on the prostate-specific antigen (PSA) response to testosterone replacement therapy.
    Rhoden EL; Morgentaler A
    Int J Impot Res; 2006; 18(2):201-5. PubMed ID: 16177827
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.